...
MLYSMID

Mineralys Therapeutics, Inc.

HealthcareBiotechnology
$29.26
$0.00(+0.79%)
52W$8.69
$47.65
FinancialsValuationvs UTHR
Updated Mar 1, 12:00 AM
RSI44
RS Rating81/99
Beta0.40
Volatility114%
F-Score1/9
Mkt Cap$2.3B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Mineralys Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings growth of 54% provides fundamental context to the price action. Investors should exercise caution due to high volatility (114% annualized), which requires wider risk management.

Relative Strength
81
out of 99
Market Leader
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.40
vs S&P 500
LOW VOL
52W Position
53%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$32.47
50 SMA > 100 SMA$36.66
100 SMA > 150 SMA$33.01
150 SMA > 200 SMA$28.45

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$29.43-0.59%BELOW
50 SMA$32.47-9.88%BELOW
100 SMA$36.66-20.18%BELOW
150 SMA$33.01-11.36%BELOW
200 SMA$28.45+2.86%ABOVE

Price Performance

1D+0.8%
1W+1.1%
1M-9.5%
3M-32.1%
6M+92.2%
YTD-18.1%
1Y+220.1%
3Y+18.1%
52-Week Trading Range53% from low
$29.26
52W Low$8.69
52W High$47.65

Technical Indicators

RSI (14)NEUTRAL
43.5
305070
VCP ScoreCOOL
4/10
Base depth: 47.0%

Risk Profile

Beta
0.40
52W Vol
114%
ATR
$1.50
Max DD (1Y)
-42%

Volume Analysis

Today
29
50D Avg
1.00M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q4'24-61%
$-0.98
Q1'25-13%
$-0.79
Q2'25+20%
$-0.66
Q3'25+54%
$-0.52
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:—

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+9.79%

Stock Price CAGR

10 Years:+4.73%
5 Years:+9.67%
3 Years:+18.06%
1 Year:+220.13%

Return on Equity

10Y Avg:-79.2%
5Y Avg:-79.2%
3Y Avg:-79.2%
Last Year:-29.7%

Key Metrics

Market Cap$2.3B
Gross Margin—
Net Margin—
Piotroski F-Score1/9

More MLYS Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

MLYS vs UTHRUTHRZLABAMRNALKS

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 81 meansMLYS outperformed 81% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.40 means 60% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 1/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is MLYS in an uptrend right now?

MLYS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is MLYS overbought or oversold?

MLYS's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.

Is MLYS outperforming the market?

MLYS has a Relative Strength (RS) Rating of 81 out of 99. Yes, MLYS is a market leader, outperforming 81% of all stocks over the past 12 months.

Where is MLYS in its 52-week range?

MLYS is trading at $29.26, which is 61% of its 52-week high ($47.65) and 53% above its 52-week low ($8.69).

How volatile is MLYS?

MLYS has a Beta of 0.40 and 52-week volatility of 114%. It's less volatile than the S&P 500 - generally more stable.